Table 2.
Patient characteristics with rheumatoid arthritis only.
| At the age of RA onset | Comorbidity | Immunoserology | DMARD therapy | Response to DMARD | Corticosteroids (mg PED) | Biological therapy | Response to biology therapy |
|---|---|---|---|---|---|---|---|
| 63 yrs | Hypertension | RF, ACPA | Sulfasalazine-ineffective, leflunomide-allergic side effect, oral methotrexate | Partial response | <7.5 | Tocilizumab | Remission |
|
| |||||||
| 46 yrs | — | RF, ACPA, ANA | Combination of oral methotrexate and chloroquine | Remission | 10 | — | — |
|
| |||||||
| 59 yrs | Sjögren's syndrome | RF, ACPA, ANA | Combination of oral methotrexate and chloroquine | Remission | 10 | — | — |
|
| |||||||
| 32 yrs | — | RF, ACPA, ANA | Combination of subcutaneous methotrexate and chloroquine | Remission | — | — | — |
|
| |||||||
| 40 yrs | — | RF, ACPA | Subcutaneous methotrexate | Remission | — | — | — |
RA: rheumatoid arthritis, ANA: anti-nuclear antibody, ACPA: anti-citrullinated peptide antibody, DMARD: disease-modifying antirheumatic drugs, and PED: prednisolone equivalent dose.